APT vs SRPT

For growth investors, Sarepta Therapeutics, Inc.

(SRPT) is the stronger pick with 15. 6% revenue growth year-over-year, versus 2. 3% for Alpha Pro Tech, Ltd. (APT). Alpha Pro Tech, Ltd. (APT) offers the better valuation at 19. 6x trailing P/E, making it the more compelling value choice. Analysts rate Sarepta Therapeutics, Inc. (SRPT) a "Buy" — based on 54 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Alpha Pro Tech, Ltd.

(APT) delivered a total return of -24. 7%, compared to -72. 1% for Sarepta Therapeutics, Inc. (SRPT). Over 10 years, the gap is even starker: APT returned +209. 1% versus SRPT's +13. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Alpha Pro Tech, Ltd.

(APT) is the lower-risk stock at 0. 39β versus Sarepta Therapeutics, Inc. 's 1. 95β — meaning SRPT is approximately 396% more volatile than APT relative to the S&P 500. On balance sheet safety, Alpha Pro Tech, Ltd. (APT) carries a lower debt/equity ratio of 13% versus 91% for Sarepta Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Sarepta Therapeutics, Inc.

(SRPT) is pulling ahead at 15. 6% versus 2. 3% for Alpha Pro Tech, Ltd. (APT). On earnings-per-share growth, the picture is similar: Alpha Pro Tech, Ltd. grew EPS -5. 7% year-over-year, compared to -404. 7% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, SRPT leads at 33. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alpha Pro Tech, Ltd.

(APT) is the more profitable company, earning 6. 0% net margin versus -32. 5% for Sarepta Therapeutics, Inc. — meaning it keeps 6. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: APT leads at 6. 5% versus -29. 9% for SRPT. At the gross margin level — before operating expenses — SRPT leads at 59. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Alpha Pro Tech, Ltd.

(APT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 39), +209. 1% 10Y return). Sarepta Therapeutics, Inc. (SRPT) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (APT: +209. 1%, SRPT: +13. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (APT (Industrials) and SRPT (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: APT is a small-cap quality compounder stock; SRPT is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.